CAR-T Cell Therapy in Uttar Pradesh — Dr. Faran Naim, Hematology & Bone Marrow Transplant Specialist, Jigyasa Hospital
For patients across Uttar Pradesh living with certain relapsed or hard-to-treat blood cancers, CAR-T cell therapy represents one of the most significant recent advances in cancer treatment — a personalized, cell-based therapy that has achieved remission in patients who had exhausted other options.
While the therapy itself is delivered at specialized centers, patients from Moradabad, Rampur, Sambhal, Amroha, Bijnor, and across the wider state don't have to navigate the process alone. Dr. Faran Naim, Hematology & Bone Marrow Transplant specialist at Jigyasa Hospital, helps patients understand whether CAR-T therapy is a fit for their situation, prepares them for the process, coordinates referral to an appropriate center, and manages ongoing follow-up care once treatment is complete.
What Is CAR-T Cell Therapy?
CAR-T cell therapy, short for Chimeric Antigen Receptor T-cell therapy, is a form of immunotherapy that uses a patient's own immune cells, reprogrammed in a laboratory, to fight cancer. Unlike traditional chemotherapy or even standard immunotherapy drugs, CAR-T therapy is a "living drug" — the treatment itself consists of the patient's own genetically modified cells.
The process works by extracting T cells (a type of white blood cell central to immune defense) from the patient's blood, genetically engineering them in a specialized laboratory to express a receptor that recognizes a specific marker found on cancer cells, multiplying these modified cells to large numbers, and then infusing them back into the patient. Once reinfused, these engineered T cells circulate through the body, seek out cancer cells carrying the target marker, and destroy them.
Which Conditions Is CAR-T Therapy Used For?
CAR-T cell therapy is currently approved and most established for certain blood cancers that have relapsed or not responded to standard treatment, including:
Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Particularly in patients, including children and young adults, who have not achieved remission with standard chemotherapy or have relapsed after initial treatment.
Relapsed or Refractory Large B-Cell Lymphoma
A subtype of non-Hodgkin lymphoma where CAR-T therapy has shown meaningful results in patients who have not responded to, or have relapsed after, standard chemotherapy and other treatments.
Relapsed or Refractory Multiple Myeloma
Increasingly used in myeloma patients who have gone through multiple prior lines of treatment without achieving durable remission.
Other Emerging Indications
Research into CAR-T therapy for additional blood cancers and even certain other conditions is ongoing, and the range of approved uses continues to expand.
CAR-T therapy is generally considered after standard treatments, including chemotherapy, immunotherapy, and sometimes stem cell transplant, have been tried without achieving a lasting remission — it is not typically a first-line option.
Who Is a Candidate for CAR-T Cell Therapy?
Determining candidacy involves a careful, individualized evaluation, which Dr. Naim conducts as the first step in the referral process:
Confirmed Diagnosis and Disease Marker Testing
The specific blood cancer and the presence of the relevant target marker on cancer cells must be confirmed through diagnostic testing.
Treatment History
A review of prior treatments received and how the disease responded, since CAR-T therapy is generally considered for relapsed or treatment-resistant disease.
Overall Health and Organ Function
Given the intensity of the CAR-T process, adequate heart, lung, kidney, and liver function are important considerations, along with overall fitness to tolerate the treatment and its potential side effects.
Disease Burden at the Time of Evaluation
The extent and location of active disease can influence both eligibility and the timing of the procedure.
Logistical and Support Considerations
Because CAR-T therapy requires travel to a specialized center and a period of close monitoring afterward, having a clear support plan — including caregiver availability and a place to stay near the treatment center during the required observation period — is part of practical planning.
The CAR-T Cell Therapy Process, Step by Step
1. Initial Evaluation and Referral
Dr. Naim reviews the patient's diagnosis, treatment history, and overall health to determine if CAR-T therapy is a reasonable option, and facilitates referral to a specialized center offering the therapy.
2. Pre-Treatment Workup at the Specialized Center
Includes confirmation of eligibility, detailed organ function testing, and disease marker confirmation specific to the CAR-T product being used.
3. T-Cell Collection (Leukapheresis)
A procedure similar to a blood donation, where blood is drawn, T cells are separated out, and the remaining blood components are returned to the patient. This typically takes a few hours.
4. Cell Manufacturing
The collected T cells are sent to a specialized laboratory where they are genetically engineered and multiplied. This manufacturing process can take several weeks, during which some patients may need bridging therapy to help control their disease while waiting.
5. Conditioning Chemotherapy
A short course of chemotherapy given shortly before the CAR-T cell infusion, intended to reduce the number of existing immune cells and create favorable conditions for the engineered cells to expand once infused.
6. CAR-T Cell Infusion
The manufactured cells are infused back into the patient, a process similar to a blood transfusion.
7. Close Monitoring Period
Following infusion, patients require close monitoring, typically as an inpatient, for potential side effects such as cytokine release syndrome and neurological effects, which can occur in the days following treatment and require prompt specialized management.
8. Recovery and Follow-Up
After the initial monitoring period at the treatment center, patients typically return home, with Dr. Naim continuing long-term follow-up, monitoring blood counts, immune recovery, and disease response, coordinating with the treating center as needed.
Potential Side Effects of CAR-T Therapy
CAR-T therapy carries a distinct side effect profile that requires specialized management, primarily during and shortly after the infusion period:
Cytokine Release Syndrome (CRS)
An immune-related reaction that can cause fever, low blood pressure, and other symptoms as the engineered T cells become active. This is closely monitored and managed at the treatment center.
Neurological Effects
Some patients experience temporary confusion, difficulty with speech, or other neurological symptoms following infusion, which are monitored closely and are generally reversible with appropriate management.
Low Blood Counts
Similar to chemotherapy, CAR-T therapy can cause a temporary drop in blood cell counts, requiring monitoring and sometimes transfusion support.
Increased Infection Risk
Due to the conditioning chemotherapy and the treatment's effect on the immune system, patients have an elevated infection risk for a period of time following treatment.
Long-Term Monitoring Needs
Patients who have undergone CAR-T therapy require ongoing follow-up to monitor disease response and watch for any delayed effects, which Dr. Naim provides as part of continued hematology care.
Specialist Guidance from the Start
Dr. Naim's hematology and transplant expertise means patients across Uttar Pradesh get an informed, realistic assessment of whether CAR-T therapy is appropriate for their situation, rather than navigating this decision without specialist input.
Reliable Diagnostic Support
Jigyasa Hospital's NABL-accredited laboratory supports the diagnostic testing needed both before referral and during ongoing follow-up care.
Reduced Travel Burden
By managing evaluation, bridging therapy, and long-term follow-up locally, patients and families can minimize the amount of time spent away from home to what's strictly necessary for the treatment itself.
24/7 Emergency Care
For any complications arising during bridging therapy or after returning home following CAR-T treatment, Jigyasa Hospital's round-the-clock emergency services provide an important local safety net.
Trusted CAR-T Evaluation and Coordination in Uttar Pradesh
Patients from Moradabad, Rampur, Sambhal, Amroha, Bijnor, and across Uttar Pradesh choose Jigyasa Hospital for specialist CAR-T evaluation, NABL lab, PM-JAY empanelment, and comprehensive support.
The Role of Jigyasa Hospital in the CAR-T Journey
While the CAR-T infusion itself takes place at a specialized center, much of the patient's overall care journey can be managed closer to home:
Initial Evaluation and Education
Helping patients and families understand whether CAR-T therapy is a realistic and appropriate option, and what the process involves.
Coordinating Referral
Facilitating the referral process to a center offering CAR-T therapy, including sharing relevant diagnostic and treatment history.
Bridging Therapy
Managing disease control with chemotherapy or other treatments during the manufacturing waiting period, when needed, to keep the disease in check before the CAR-T infusion.
Post-Treatment Follow-Up
Once the initial monitoring period at the treatment center is complete, Dr. Naim provides ongoing follow-up care, blood count monitoring, and management of any longer-term effects, reducing the need for repeated long-distance travel for routine follow-up visits.
Why Choose Jigyasa Hospital for CAR-T Evaluation and Coordination
CAR-T therapy is a complex, highly specialized treatment, and having expert guidance throughout the journey is invaluable. Jigyasa Hospital, located on Rampur Road near Miglani Cinema, Moradabad, offers comprehensive CAR-T evaluation and coordination under Dr. Faran Naim, keeping as much of the journey as possible close to the patient home and family.
- • Specialist Guidance from the Start: Dr. Naim's hematology and transplant expertise means patients across Uttar Pradesh get an informed, realistic assessment of whether CAR-T therapy is appropriate for their situation, rather than navigating this decision without specialist input.
- • Reliable Diagnostic Support: Jigyasa Hospital's NABL-accredited laboratory supports the diagnostic testing needed both before referral and during ongoing follow-up care.
- • Reduced Travel Burden: By managing evaluation, bridging therapy, and long-term follow-up locally, patients and families can minimize the amount of time spent away from home to what's strictly necessary for the treatment itself.
- • Ayushman Bharat PM-JAY Empanelment: While CAR-T therapy costs and coverage vary and depend on the treating center, Jigyasa Hospital's PM-JAY empanelment supports accessibility for other aspects of eligible patients' overall care.
- • 24/7 Emergency Care: For any complications arising during bridging therapy or after returning home following CAR-T treatment, Jigyasa Hospital's round-the-clock emergency services provide an important local safety net.
Book an Appointment with Dr. Faran Naim
Jigyasa Hospital offers specialist hematology and CAR-T cell therapy evaluation under the guidance of Dr. Faran Naim. From initial assessment and referral coordination to bridging therapy and long-term follow-up, comprehensive support is available close to home.
Near Miglani Cinema, Rampur Road, Moradabad 244001
Call Now
7900903333Frequently Asked Questions
Is CAR-T cell therapy available in Moradabad?
CAR-T cell therapy itself is administered at specialized centers with the required manufacturing and monitoring infrastructure. Dr. Naim at Jigyasa Hospital provides evaluation, referral coordination, bridging therapy, and post-treatment follow-up care in Moradabad.
Who is a good candidate for CAR-T therapy?
Candidates are generally patients with certain relapsed or treatment-resistant blood cancers, such as specific types of leukemia, lymphoma, or myeloma, who have already tried standard treatments without achieving lasting remission, and who are otherwise fit enough to tolerate the process.
How long does the entire CAR-T process take?
From initial evaluation through cell collection, manufacturing (often several weeks), conditioning chemotherapy, infusion, and the required monitoring period, the overall process can take anywhere from several weeks to a few months, depending on individual circumstances.
Is CAR-T therapy the same as a stem cell transplant?
No. Stem cell transplant replaces the bone marrow's blood-forming cells, while CAR-T therapy uses genetically engineered immune cells to specifically target and destroy cancer cells. They are distinct approaches, though a patient's treatment history may include either or both.
What are the main risks of CAR-T therapy?
The most notable risks include cytokine release syndrome and temporary neurological effects, both of which require close monitoring, typically as an inpatient, in the days following infusion.
Can I continue seeing my regular hematologist after CAR-T treatment?
Yes. Long-term follow-up after CAR-T therapy, including blood count monitoring and disease response assessment, can be coordinated with your local hematologist, allowing most routine follow-up to happen closer to home.
What is bridging therapy, and why is it sometimes needed?
Bridging therapy refers to treatment given to help control the cancer while the patient's engineered CAR-T cells are being manufactured, a process that can take several weeks, to prevent the disease from progressing significantly during the waiting period.
How do I find out if CAR-T therapy is right for me or a family member?
The first step is a hematology evaluation to review the diagnosis, treatment history, and overall health, which will determine whether referral for CAR-T therapy evaluation at a specialized center is appropriate.
Why Patients Choose Us
- 24/7 Emergency & Trauma Care
- Top Specialist Doctors
- Modern ICU & Operation Theatres
- Transparent & Affordable Pricing
- Ayushman Bharat Empanelled
- Cashless Insurance Support
- Multispeciality Under One Roof
Our Location
Near Miglani Cinema,
Rampur Road,
Moradabad 244001